Life-saving therapeutics continue to grow more costly to discover. At the same time, recent advances in using machine learning for the life sciences and medicine are extraordinary. Are we on the verge of a paradigm shift in biotech?
This week on the podcast, a pioneer in AI, Daphne Koller, joins Sarah Guo and Elad Gil on the podcast to help us explore that question. Daphne is the CEO and founder of Insitro — a company that applies machine learning to pharma discovery and development, specifically by leveraging “induced pluripotent stem cells.” We explain Insitro’s approach, why they’re focused on generating their own data, why you can’t cure schizophrenia in mice, and how to design a culture that supports both research and engineering. Daphne was previously a computer science professor at Stanford, and co-founder and co-CEO of edutech company Coursera.
00:00 - Introduction
01:49 - How Daphne combined her biology and tech interests and ran a bifurcated lab at Stanford
04:34 - Why Daphne resigned an endowed chair at Stanford to build Coursera
14:14 - How insitro approaches target identification problems and training data
18:33 - What are pluripotent stem cells and how insitro identifies individual neurons
24:08 - How insitro operates as an engine for drug discovery and partners to create the drugs themselves
26:48 - Role of regulations, clinical trials and disease progression in drug delivery
33:19 - Building a team and workplace culture that can bridge both bio and computer sciences
39:50 - What Daphne is paying attention to in the so-called golden age of machine learning
43:12 - Advice for leading a startup in edtech and healthtech
